FAMCICLOVIR IN THERAPY OF ATOPIC DERMATITIS PATIENTS WITH HERPES SIMPLEX INFECTION



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The prevalence of herpes simplex virus in different age groups, the high frequency of relapsing forms of infection, torpid course, postherpetic complications are relevant medical and social problems. Often, practitioners create significant difficulties in establishing the diagnosis, choice of strategy in patients with herpes simplex. The paper presents the methods of diagnosis of herpes simplex and their application in atopic dermatitis patients, issues of acyclic nucleoside therapy (acyclovir, famciclovir) in different clinical forms of herpes simplex with individual approach to the selection of an antiviral drug and patterns of use.

Full Text

Restricted Access

About the authors

I N Zuikova

Institute of Immunology

Email: zuikova_i@mail.ru
Moscow, Russia

A E Shulzhenko

Institute of Immunology

Moscow, Russia

E S Fedenko

Institute of Immunology

Moscow, Russia

O G Elisutina

Institute of Immunology

Moscow, Russia

References

  1. Ring J., Alomar A., Bieber T. et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part I. J. Eur. Acad. Dermatol Venereol. 2012, v. 26 (8), p. 1045-1060.
  2. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006, v. 38 (4), p. 441-446.
  3. Elias Peter M., Schmuth Matthias. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2009, v. 9 (5), p. 437-446.
  4. Bieber T. Atopic dermatitis. N. Engl. J. Med. 2008, v. 358, p.1483-1494
  5. Beck L.A., Boguniewicz M., Hata T. et al. Phenotype ofatopic dermatitis subjects with a history of eczema herpeticum. J. Allergy Clin. Immunol. 2009, v. 124, p. 260-269.
  6. Гомберг М.А. Рекомендации по ведению больных с генитальным герпесом: чему учит мировой опыт. Рос. журн. кожных и венерических болезней. Приложение: Герпес. 2009, № 2, с. 57-62.
  7. Cunningham A.L., Mikloska Z. The holy grail: immune control of human herpes simplex virus infection and disease. HERPES. 2001, v. 8, No. 1, p. 6A-10A.
  8. Drake A.L. et al. Herpes simplex virus type 2 and the risk of intrapartum human immunodeficiency virus transmission. Obstet. Gynecol. 2007, v. 109, Iss. 2, Part. 1, p. 403-409.
  9. Шульженко А.Е. Герпетические инфекции человека: перспективы диагностики и противовирусной терапии. Цитикины и воспаление. 2005, № 3, с. 76-81.
  10. Corey L. и соавт. Снижение риска передачи генитального герпеса при ежедневном приеме валацикловира. Рос. журн. кожных и венерических болезней. Приложение: Герпес. 2006, No. 2, с. 59-64.
  11. Lowhagen G.B., Tunback P., Bergstrom T. Proportion of herpes simplex virus (HSV) type 1 and type 2 among genital and extragenital HSV isolates. Acta Derm. Venereol. 2002, v. 82, No. 2, p. 118-120.
  12. Львов А.Н., Халдин А.А., Федякова Е.В. Рецидивирующий простой герпес: клинико-психоиммунные соотношения на фоне комплексной терапии. Рос. журн. кожных и венерических болезней. Приложение: Герпес. 2006, № 1, с. 36-40.
  13. Aoki F.Y. The continuing evolution of antiviral therapy for recurrent genital herpes: 1-day patient-initiated treatment with famciclovir. Herpes. 2007, v. 14 (3), p. 62-65.
  14. Crumpacker C.S. Use ofantiviral drugs to prevent herpesvirus transmission. N. Engl. J. Med. 2004, v. 350, No. 1, p. 67-68.
  15. Самгин М.А., Халдин А.А. Простой герпес. Дерматологические аспекты. М., «МЕДпресс-информ». 2002, 160 с.
  16. Gupta R., Warren T., Wald A. Genital herpes. Lancet. 2007, v. 370, No. 9605, p. 2127-2137.
  17. Wald A., Selke S., Warren T. et al. Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding. Sex. Transm. Dis. 2006, Mar 8.
  18. Европейские стандарты диагностики и лечения ЗППП. HTML format (сайт www.iusti.org), декабрь 2010 г.
  19. Abudalu M. et al. Single-day, patient-initiated famciclovir therapy versus 3-day valaciclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin. Infect. Dis. 2008, v. 47, No. 5, p. 651-658.
  20. Bodsworth N. et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sexual Health. 2008, v. 5, No. 3, p. 219-225.
  21. De Clercq E. Selective anti-herpesvirus agents. Antivir Chem Chemother. 2013, Jan 23.
  22. Sheffield J.S. et al. Valacylovir prophylaxis to prevent recurrent herpes at delivery: a randomised clinical trial. Obstet. Gynecol. 2006, v. 108, No. 1, p. 141-147.
  23. Langley R.G. Famciclovir for the treatment of recurrent genital and labial herpes lesions. Skin. Therapy Lett. 2005—2006, v. 10 (10), p. 5-7.
  24. Diaz-Mitoma F. и соавт. Пероральный прием фамцикловира для лечения рецидивирующего генитального герпеса: рандомизированное контролируемое исследование. Рос. журн. кожных и венерических болезней. Приложение: Герпес. 2008, № 1, с. 33-39.
  25. Bartlett B.L., Tyring S.K., Fife K. et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J. Clin. Virol. 2008, v. 43 (2), p. 190-195.
  26. Aoki F.Y. et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebocontrolled trial. Clin. Infect. Dis. 2006, v. 42, No. 1, p. 8-13.
  27. Leone P., Warren T., Hamed K. et al. Famciclovir reduces viral mucosal shedding in HSV-seropositive persons. Sex Transm Dis. 2007, v. 34 (11), p. 900-907.
  28. Block S.L., Yogev R., Waldmeier F., Hamed K. Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis. Pediatr. Infect. Dis. 2011, v. 30 (6), p. 525-528.
  29. Patel R. Making the most of episodic antiviral therapy for genital herpes. Sexual Health. 2008, v. 5, p. 213-214.
  30. Modi S., Van L., Gewirtzman A., Mendoza N. et al. Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology. Ther. Clin. Risk Manag. 2008, v. 4 (2), p. 409-417.
  31. Wald A. et al. Two-day regimen of aciclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin. Infect. Dis. 2002, v. 34, No. 7, p. 944-948.
  32. Sacs S.L., Aoki F.Y., Martel A.Y. et al. Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes a randomized, double-blind, controlled trial. Clin. Infect. Dis. 2005, v. 41 (8), p. 1097-1014.
  33. Шульженко А.Е., Зуйкова И.Н. Психосоциальные аспекты генитальной герпес-вирусной инфекции. Рос. журн. кожных и венерических болезней. Приложение: Герпес. 2007, № 1, с. 13-18.
  34. Lebrun-Vignes B. et al. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J. Am. Acad. Dermatol. 2007, v. 57, Iss. 2, p. 238-246.
  35. Bodsworth N., Fife K., Koltun W et al. Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. Curr. Med. Res. Opin. 2009, v. 25 (2), p. 483-487.
  36. Geretti A.M. Genital herpes. Part 2: Testing guidelines for individual sexually transmitted infections. Sex. Transm. Infect. 2006, v. 82, Suppl. 4, p. iv31-34.

Copyright © Pharmarus Print Media, 2013



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies